Comparison of Interleukin-33 Serum Levels in Patients with Breast Cancer and Idiopathic Granulomatous Mastitis.
Interleukin-33
breast cancer
idiopathic granulomatous mastitis
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 May 2023
01 May 2023
Historique:
received:
21
11
2022
medline:
31
5
2023
pubmed:
29
5
2023
entrez:
29
5
2023
Statut:
epublish
Résumé
Breast cancer (BC) is the main cause of cancer death in women. Idiopathic granulomatous mastitis (IGM), a rare chronic disease that clinically mimics breast carcinoma, and is associated with high mortality and morbidity, but an immediate and accurate diagnosis can substantially decrease these rates. Expressed by numerous human tissues, interleukin-33 (IL-33) has an inductive role in the network of pro-inflammatory cytokines. The aim of this study was to investigate the serum levels of IL-33 in BC and IGM patients in comparison with healthy women. This descriptive-analytical study was carried out on 28 patients with BC and 25 patients with IGM as the patient groups and 25 healthy volunteers with normal screening reports as the control group. Histopathological pattern of BC and IGM were confirmed by specialized pathologists. The serum concentration of IL-33 was measured using enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions. The mean age of the patients with BC and IGM and the control group was 49.1, 37.1, and 36.8 years, respectively. There was no significant difference in IL-33 expression among the participants with regard to age, marital status, body mass index (BMI), and menopausal status. IL-33 assay indicated a significant difference between the BC (P=0.011) and IGM (P=0.031) groups compared to the controls, although no substantial differences were observed between the IGM and BC groups. IL-33 can be considered a significant factor distinguishing IGM and BC patients from controls, although it cannot be applied to diagnose and differentiate BC from IGM patients.<br />.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer (BC) is the main cause of cancer death in women. Idiopathic granulomatous mastitis (IGM), a rare chronic disease that clinically mimics breast carcinoma, and is associated with high mortality and morbidity, but an immediate and accurate diagnosis can substantially decrease these rates. Expressed by numerous human tissues, interleukin-33 (IL-33) has an inductive role in the network of pro-inflammatory cytokines. The aim of this study was to investigate the serum levels of IL-33 in BC and IGM patients in comparison with healthy women.
MATERIALS AND METHODS
METHODS
This descriptive-analytical study was carried out on 28 patients with BC and 25 patients with IGM as the patient groups and 25 healthy volunteers with normal screening reports as the control group. Histopathological pattern of BC and IGM were confirmed by specialized pathologists. The serum concentration of IL-33 was measured using enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions.
RESULTS
RESULTS
The mean age of the patients with BC and IGM and the control group was 49.1, 37.1, and 36.8 years, respectively. There was no significant difference in IL-33 expression among the participants with regard to age, marital status, body mass index (BMI), and menopausal status. IL-33 assay indicated a significant difference between the BC (P=0.011) and IGM (P=0.031) groups compared to the controls, although no substantial differences were observed between the IGM and BC groups.
CONCLUSION
CONCLUSIONS
IL-33 can be considered a significant factor distinguishing IGM and BC patients from controls, although it cannot be applied to diagnose and differentiate BC from IGM patients.<br />.
Identifiants
pubmed: 37247282
doi: 10.31557/APJCP.2023.24.5.1629
pmc: PMC10495896
pii:
doi:
Substances chimiques
Immunoglobulin M
0
Interleukin-33
0
IL33 protein, human
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1629-1634Références
Int J Mol Sci. 2018 Sep 09;19(9):
pubmed: 30205617
Asian Pac J Cancer Prev. 2019 Jul 01;20(7):2015-2020
pubmed: 31350959
Oncotarget. 2016 Sep 20;7(38):61069-61080
pubmed: 27517629
Cells. 2022 Jul 15;11(14):
pubmed: 35883653
J Coll Physicians Surg Pak. 2022 Jul;32(7):869-873
pubmed: 35795934
J Drug Target. 2016;24(5):373-85
pubmed: 26362595
Mediterr J Hematol Infect Dis. 2021 Jul 01;13(1):e2021049
pubmed: 34276918
Tumour Biol. 2016 Aug;37(8):10021-39
pubmed: 27155851
Curr Pharm Des. 2017;23(12):1845-1859
pubmed: 28231756
Nat Commun. 2015 Sep 14;6:8327
pubmed: 26365875
Sensors (Basel). 2017 Jul 05;17(7):
pubmed: 28678153
Clin Case Rep. 2022 Sep 12;10(9):e6323
pubmed: 36172329
Case Rep Rheumatol. 2018 Dec 27;2018:4264012
pubmed: 30687557
Br J Cancer. 2019 Jan;120(1):6-15
pubmed: 30413827
Breast Cancer Res Treat. 2020 Apr;180(2):481-490
pubmed: 32056055
J Intern Med. 2011 Jan;269(1):29-35
pubmed: 21158975
J Surg Case Rep. 2021 Dec 07;2021(12):rjab519
pubmed: 34888031
Breast. 2007 Dec;16 Suppl 2:S27-33
pubmed: 17764938
Int J Mol Sci. 2021 May 28;22(11):
pubmed: 34071419
J Immunol. 2011 Aug 15;187(4):1609-16
pubmed: 21734074
Biochem Biophys Res Commun. 2017 Apr 8;485(3):643-650
pubmed: 28216163
Genomics. 2000 Aug 1;67(3):284-90
pubmed: 10936050
Cell Signal. 2014 Nov;26(11):2350-7
pubmed: 25093807
N Engl J Med. 2018 Jun 14;378(24):2311-2320
pubmed: 29897847
J Gen Intern Med. 2010 Mar;25(3):270-3
pubmed: 20013067
Breast Care (Basel). 2018 Dec;13(6):413-418
pubmed: 30800035
Breast J. 2004 Jul-Aug;10(4):318-22
pubmed: 15239790
J Immunol. 2015 Jan 1;194(1):438-45
pubmed: 25429071
BMC Cancer. 2014 Mar 18;14:198
pubmed: 24636276
Breast J. 2019 Nov;25(6):1245-1250
pubmed: 31273861
J Invest Surg. 2017 Aug;30(4):272-276
pubmed: 27780363
Nat Rev Immunol. 2016 Nov;16(11):676-689
pubmed: 27640624
Asian Pac J Cancer Prev. 2022 Aug 01;23(8):2851-2856
pubmed: 36037143
Front Immunol. 2018 Dec 20;9:3051
pubmed: 30619376
Asian Pac J Cancer Prev. 2020 Jul 01;21(7):1867-1875
pubmed: 32711409
Cytokine Growth Factor Rev. 2015 Dec;26(6):615-23
pubmed: 26271893
Dis Markers. 2015;2015:516895
pubmed: 26456994
Asian Pac J Cancer Prev. 2021 May 01;22(5):1573-1579
pubmed: 34048188
Immunol Res. 2012 Apr;52(1-2):89-99
pubmed: 22392053